693 related articles for article (PubMed ID: 18938248)
1. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
2. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
3. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
5. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
7. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
[TBL] [Abstract][Full Text] [Related]
8. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
[TBL] [Abstract][Full Text] [Related]
10. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
11. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Epstein-Barr virus recombinants with deletions of the BamHI C promoter.
Swaminathan S
Virology; 1996 Mar; 217(2):532-41. PubMed ID: 8610445
[TBL] [Abstract][Full Text] [Related]
14. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
[TBL] [Abstract][Full Text] [Related]
15. The immunology of Epstein-Barr virus infection.
Moss DJ; Burrows SR; Silins SL; Misko I; Khanna R
Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):475-88. PubMed ID: 11313006
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
17. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.
D'Orsogna LJ; Amir AL; Zoet YM; van der Meer-Prins PM; van der Slik AR; Kester MG; Heemskerk MH; Doxiadis II; Roelen DL; Claas FH
Tissue Antigens; 2009 Oct; 74(4):290-7. PubMed ID: 19624615
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.
Hellebrand E; Mautner J; Reisbach G; Nimmerjahn F; Hallek M; Mocikat R; Hammerschmidt W
Gene Ther; 2006 Jan; 13(2):150-62. PubMed ID: 16136164
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.
Hammerschmidt W; Sugden B
Nature; 1989 Aug; 340(6232):393-7. PubMed ID: 2547164
[TBL] [Abstract][Full Text] [Related]
20. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
